前苏联专利SU1584750A3 Method of producing derivatives of 3(2n)-pyridazinone

专利PDF首页>>前苏联专利

专利附录

专利说明

权利要求

类似技术

同族专利

引用文献

法律状态

优先权

专利摘要:
A 3(2H)pyridazinone of the formula: <CHEM> wherein R1 is hydrogen, 2-propenyl or straight chained or branched C1-C4 alkyl; R2 is hydrogen or C1-C3 alkyl; X is chlorine or bromine; Y is hydrogen, nitro, -NHR3 wherein R3 is hydrogen or straight chained or branched C1-C4 alkyl, -AR4 wherein A is oxygen or sulfur and R4 is hydrogen, straight chained or branched C1-C6 alkyl, C3-C6 alkenyl having one double bond, C3-C6 alkynyl having one triple bond, phenyl or <CHEM> wherein R5 is hydrogen or C1-C4 alkyl, or halogen; Z1 is hydrogen, C1-C4 alkyl, -OR6 wherein R6 is hydrogen, straight chained or branched C1-C8 alkyl or <CHEM> wherein n is an integer of from 1 to 4, -N(R7)2 wherein R7 is C1-C4 alkyl, or halogen; Z2 is C1-C4 alkyl, -OR6 wherein R6 is as defined above, -N(R7)2 wherein R7 is as defined above, or halogen, provided that when R1 is straight chained or branched C2-C4 alkyl, Y is not hydrogen and when R1 is hydrogen, methyl or 2-propenyl, Y and R2 are not simultaneously hydrogen, or a pharmaceutically acceptable salt thereof.
公开号:SU1584750A3
申请号:SU884355078
申请日:1988-01-19
公开日:1990-08-07
发明作者:Таникава Кейзо；Сакода Риозо；- Ити Сикада Кен；Танака Сакуя
申请人:Ниссан Кемикал Индастриз, Лтд.(Фирма)；
IPC主号:

专利说明:

This invention relates to a process for the preparation of new 3 (2H) -pyridazinone derivatives, which show antagonism against a slow-acting anaphylactic (SRS-A) 0 substance.
The purpose of the invention is to obtain new 3 (2H) -pyridazinone derivatives, 10 exceeding the known structural analogues in their biological activity, possessing the same type of activity.
Example 1 (control). 2- -Ethyl-4,5-dichloro-6-hydroxy-3 (2H) -pyri-15 dazinone.
A mixture containing 5.00 g of 3,6-dioxy-4,5-dichloropyridazine, 2.21 g of sodium hydroxide, 5.60 g of ethyl iodide, 40 ml of ethanol and water is stirred at 60-70 ° C for 4 hours. Most of the ethanol is distilled off under reduced pressure. Diluted hydrochloric acid and chloroform are then added to the residue, and 25 mixture is shaken vigorously. The chloroform layer is separated and washed with water and then dried with sodium sulfate. The solvent is distilled to obtain a light orange solid, 30 which is treated with benzene to form. 3.56 g of the title compound as colorless crystals.
Nuclear Magnetic Resonance Spectrum (CDC1, + DMSO - dt): 4.05 (2H, g), 1.33 (3H, t) .35
Infrared spectrum (Owc (Kc, cm f): 3150, 1635, 1620, 1560, 1510 ..
Mass spectrum (m / e): 208 (M), 193, 180 (100%), 166, 148.
PRI me R 2 (control), 4,5-40-Dichloro-6-ethoxy-3- (2H) -pyridazinone.
27.15 g of 3, b-dioxy-4,5-dichloropyridazine is dissolved in a solution obtained by dissolving 6.43 g of sodium hydroxide in 200 ml of d5 water, after which this solution is dried at a temperature below freezing point. obtaining 32.80 g of sodium salt of 3,6-dioxy-4,5-dichloropyridazine as a light yellow powder. A mixture containing 14.21 g of sodium salt, 13.10 g of ethyl iodide and 200 ml of N, N-dimethylformamide is stirred at 70-80 ° C for 4 hours. The solvent is distilled off under reduced pressure, and the residue thus obtained water is added. This mixture is extracted with chloroform. The extract is washed with a saturated aqueous solution.
0
five
0 5 0
five
0
five
0
five
sodium chloride and dried over sodium sulfate. The solvent is then distilled off to obtain a light orange solid, which is washed with 250 ml of a solvent mixture consisting of benzene and ethyl acetate (in a volume ratio of 3: 1), resulting in a yield of 2.83 g of the title compound with m.p. 212-212,5 ° C in the form of colorless crystals. The residual wash solution is treated with 10 g of silica gel, and then the solvent is distilled off to obtain a light yellow solid, which is washed with diethyl ether to form a further 2.37 g of the title compound. Overall yield: 5.20 g.
NMR spectrum (SG, C1e + DMSO-d6): 4.20 (2H, g), 1.38 (3H, t).
Infrared spectrum (Vwv «« c cm-): 2975, 2850, 1645, 1585, 1380.
Mass spectrum (m / e): 208 (M), 180 (100%), 150.
In the same way, but using iodide, isopropyl, benzyl bromide, and c-phenyl ethyl bromide instead of ethyl iodide, respectively: 4,5-dichloro-6-isopropoxy-3 (2H) -pyridazinone, mp. 210-211 ° C; 4,5-dichloro-6-benoyloxy- -3- (2H) -pyridazinone, m.p. 111-113DCS; 4,5-dichloro-b-W-methylbenzyloxy) -3 (2H) -pyridazinone, m.p. 160-161 Cj 4,5-dichloro-6- (c / -methylbenzyloxy) -3 (2H) -pyridazinone, m.p. 160-161 C.
PRI me R 3 (control). 2- (2-Trimethylsilyl ethoxymethyl) -4-chloro-5- (3-ethoxy-4-methoxybenzylamino) -6-nitro-3 (2H) -pyridazinone.
587 mg of trimethylsilyl-ethoxymethyl chloride are added to a mixture containing 500 mg of 4-chloro-5- (3-ethoxy-4-methoxybenzylamino) -6-nitro-3 (2H) -pyridazinone (compound 17), 911 mg of dnisopropylethylamine and 15 ml of dichloromethane, after which the mixture is stirred at room temperature for 10 minutes. The solvent is distilled off, and the resulting residue is extracted with chloroform. The extract is washed twice with a saturated solution of copper sulfate and once with water in this order, and then dried over sodium sulfate. Thereafter, the solvent is distilled off to obtain a yellow oily substance, which is purified by flash chromatography on silica gel using diethyl ether as a developer, to obtain 600 ml of this. compounds as a yellow oily substance. This oily substance is left to stand for the purpose of gradual transformation into crystals with m.p. 56-57.5 ° C.
NMR Spectrum: 6.85 (3H.S), 6.69 (1H, ha), 5.48 (2H, S), 4.78, 4.68 (2H, d), 4.10 (2H, g), 3.88 (3H, S), 3.80 (2H, t), 1.49 (3H, t), 1.00 (3H, t), 0.0 (9H, S).
Mass spectrum (m / e): 484 (M), 483 (100%), 353, 319.
In the same way, from 4-chloro-5- (3,4-dimethoxybenzylamino) -6-nitro-3 (2H) -pyridazinone (compound 87), 2- (2-trimethylsilyl-ethoxymethyl) -4 chloro-5- ( 3,4-dimethoxybenzylamino) -6-nitro-3 (2H) -pyridazinone (yellow oily substance).
Example (control). 2- (2-Trimethylsilyl ethoxymethyl) -4-chloro-5- (3-ethoxy-4-methoxybenzylamino) -6-methoxy-3 (2H) -pyridazinone.
A mixture containing 250 mg of 2- (2-trimethylsilyl ethoxymethyl) -4-chloro-5- (3--ethoxy-4-methoxybenzylamino) -6-nitro-3 (2H) -pyridazinone obtained in Control Example 3, 42mg sodium methoxide and methanol, stirred at room temperature for 10 minutes. Water was added to the reaction mixture, the solvent was distilled off, and the resulting residue was extracted with chloroform. The extract is washed with water and dried over sodium sulfate. The solvent is distilled off to form an oily substance, which is purified by flash chromatography on silica gel using diethyl ether as a developer, resulting in 220 mg of the title compound as a light yellow oily substance.
NMR Spectrum φ: 6.78 (3H, S), 5.30 (2H, S), 5.10 (1H, m), 4.82, 4.74 (2H, d), 4.10 (2H, g), 3.85 (6H, S), 3.72 (2H, t), 1.48 (3H, t), 1.00 (3H, t), 0.0 (9H, S).
Mass spectrum (m / e): 469 (M +), 468 (100%), 304, 188.
Also, from the corresponding 2- (2-trimethylsilyloxymethyl) -4-chloro-5- (3-alkoxy-4-methoxybenzylamino) -6-nitro-3 (2H) -pyridazines, 2- (2- -trimethylsilyl ethoxymethyl) is obtained -4-chloro-5-
- (3-ethoxy-4-methoxybenzylamino) -b- -v-butoxy-3 (2H) -pyridazinone (oily substance) and 2- (2-trimethylsilyl-ethoxymethyl) -4-chloro-5- (3,4-di - methoxybenzylamino) -6-sec-butoxy- -3 (2H) -pyridazinone, using sec, -butyl instead of sodium methoxide.
EXAMPLE 5 4-Bromo-5- (3-n-Proxy-4-methoxy-methyl benzyl amino) -3 (2H) -pyridazinone (compound 6)
0-p-Pr / Soma
0
five
0
five
0
five
A mixture containing 300 mg of 4,5-di- | bromo-3 (2H) -pyridazinone, 740 mg of 3-n-propoxy-4-methoxy-N-methylbenzylamine and 10 ml of ethanol is heated under reflux with stirring during 7 hours. Then, ethanol was distilled off under reduced pressure, diluted hydrochloric acid was added to the obtained residue, and this mixture was extracted with ethyl acetate. This extract is washed twice with water, cush, shat sodium sulfate. The solvent is then distilled off to obtain a yellow solid. This product is crystallized from ethyl acetate to form 310 mg of the title compound with a mp. 149-150 ° C in the form of light yellow crystals.
NMR spectrum: 7.53 (1H, S), 6.75 (3H, S), 4.53 (2H, S), 3.91 (2H, t), 3.81 (3H, S), 3, 01 (3H, S), 1.84 (2H, hexazalet), 1.01 (3H, t).
Mass spectrum (m / e): 302 (M + - Br, 100%), 179, 137.
Example 6 4-Chloro-5- (3-n-Propoxy-4-methoxybenzyl.mino) -6-nitro-3 (2H) -pyridazinone (compound 22)
n
, С1 0-П-Вг
50
NOW Wome N02
A mixture of 8.0 g of 4,5-dichloro-6-nitro-3 (2H) -pyridazinone, 29.75 g of 3 n-propoxy-4-methoxybenzylamine in 160 ml of ethanol is heated under reflux with stirring for 15 h. Ethanol was distilled off under reduced pressure, and water was added to the resulting residue. This mixture was extracted
chlorine The extract is washed with water and dried over sodium sulfate. Then the solvent is distilled off to form an orange solid. 6.50 g of the expected compound are obtained, m.p. 169 - 171 eС (from a mixture of mefanol - water) in the form of orange crystals.
Spectrum NMR (CDC13 + DMSO-d6) f: (0
7.01 (1Hpt), 6.77 (3H, S), 4.62 (2H, d), 3S90 (2H, t), 3.77 (3H, S), 1.78 (2H, hexazale), 1.00 (3H, t).
Mass spectrum (m / e): 368 (M), 333.179 (100%), 137., t5
Example 7. 4 Chloro-5- (3-n-propok- with |: and-4-methoxybenzylamino) -6-amino-3 (2H) -pyridazinone (compound 23)
0-n-Pt- tfoMe
1.00 4-chloro-5- (3-n-propoxy-4-methoxybenzylamino) -6-nitro-3 (2H) -pyridazinone (compound 22), prepared in Example 6, was dissolved in a solvent mixture consisting of 20 ml of ethanol and 20 ml of a 10% aqueous solution of sodium carbonate; 3.30 g of sodium bisulfite is gradually added to this solution at room temperature while stirring. This mixture was stirred at room temperature for 1 hour and neutralized with glacial acetic acid, then the ethanol was distilled off under reduced pressure. Water was added to the resulting residue, and the mixture was extracted with chloroform. The extract is washed with a saturated aqueous solution of sodium chloride and dried over sodium sulfate. Then the solvent is distilled off to form light yellow crystals. After crystallization from methanol-diethyl ether, 634 mg of the title compound are obtained with m.p. 187.5-189.5 and in the form of colorless crystals.
Mass spectrum (m / e): 338 (M), 303.179 (100%), 137.
Try on 2-Ethyl-4-chloro-5- - (3n-propoxy-4-methoxybenzylamino) -6-nitro-3 (2H) -pyridazinone (compound 24)
Јt °
t4NArCl
0-p-Pr
NY NH-CHr- (
N02

0
five
0
five
3Q 35
A mixture containing 500 mg of 4-chloro-5- - (3n-propoxy-4-methoxybenzylamino) -6-nitro-3 () -pyridazinone (compound 22) obtained in Example 6, 634 mg of ethyl iodide, 562 mg of anhydrous potassium carbonate and 25 ml of methyl ethyl ketone, heated under reflux with stirring for 1.5 hours. The solvent is distilled off under reduced pressure, water is added to the resulting residue and extracted with diethyl ether. The extract is washed with a saturated aqueous solution of sodium chloride and dried with sodium sulfate. The solvent was distilled off and the resulting residual oily substance was crystallized from a mixture of diethyl ether and n-hexane to give 473 mg of the title compound, mp. 76-77 ° C in the form of yellow crystals.
NMR spectrum: 6.79 (3H, S), 6.60 (1H, broad t), 4.68 (2H, d), 4.30 (2H, g), 3.93 (2H, t), 3 , 82 (3H, S), 1.84 (2H, hexazalet), 1.39 (3H, t), 1.03 (3H, t).
Mass spectrum (m / e): 396 (M +), 361.179 (100%), 137.
Approximately 2-Isopropyl-4-chloro-5- (3-n-propoxy-4-methoxybenzylamino) -6-nitro-3 (2H) -pyridazinone (compound 25)
from
Wg
Th
SIN 1
rcl
S NCHrO OMe N02 H

A mixture containing 500 mg of 4-chloro-5- (3-n-propoxy-4-methoxybenzylamino) -6-nitro-3 (2H) -pyridazinone (compound 22) obtained in Example 6, 691 mg of isopropyl iodide , 562 mg of anhydrous potassium carbonate and 25 ml of methyl ethyl ketone are heated under reflux with stirring for 1.5 hours. The solvent is distilled off under reduced pressure and water is added to the resulting residue. The mixture is extracted with diethyl ether. The extract is washed with a saturated aqueous sodium chloride solution, dried over sodium sulfate. Then the solvent is distilled off. The oily substance obtained is crystallized from a mixture of diethyl ether and n-hexane, and 435 mg of the title compound is obtained with a mp. 82.5-84 ° C in the form of yellow crystals.
NMR spectrum of cG: 6.80 (3H, S), 6.63 (1H, broad t), 5.25 (1H, heptalet), 4.69 (2H, d), 3.94 (2H, t), 3.83 (3H, t) 1.85 (2H, hekoalet), 1.38 (6H, d), 1.04 (3H, t).
Mass spectrum (tn / e): 410 (M +), 375, 179 (100%), 137.
Example 10. 2- (2-Propenyl) -4--chloro-5- (3-n-propoxy-4-methoxybenzylamino) -6-nitro-3 (2H) -pyridazinone (compound 26)
O.
N NCH - / 4-OMe N02H
A mixture containing 500 mg of 4-chloro-5- (3-n-propoxy) -4-methoxybenzylamino) -6-nitro-3 (2H) -pyridazinone (compound 22) obtained in Example 6, 820 mg of allyl bromide, 937 ml of anhydrous potassium carbonate and 25 ml of methyl ethyl ketone, are heated with reverse
cooler with stirring and those
1.5 h. The solvent is distilled off under reduced pressure, water is added to the residue, the mixture is extracted with diethyl ether. The extract is washed with a saturated aqueous solution of sodium chloride, the solvent is distilled off, and the residue is purified by silica gel column chromatography using a mixture solvents from benzene and ethyl acetate (85:15 mass ratio) as eluent. 394 mg of the title compound are obtained. Mp. 62.5 - 64 ° C in the form of yellow crystals.
NMR spectrum: 6.81 (3H, S), 6.59 (1H, broad t), 6.1-4.4 (7H, m), 3.95 (2H, t), 3.85 (3H, S), 1.84 (2H, hexlet), 1.02 (3H, t).
Mass spectrum (m / e): 408 (M), 373, 179 (100%), 137.
Example 11. 2-Ethyl-4-bromo-5- - (3 n-butoxy-4-methoxybenzylamino) -6-amino-3 (2H) -pyridazinone (compound 32)
0
five
0
five
five
"
five
0
ECh Vg0-n-Bu
TC SCNGO OME Sh2N
A mixture containing 280 mg of 4-bromo-5- (3-n-butoxy-4-methoxybenzylamino) -6-amino-3 (2H) -pyridazinone (compound 30), prepared in accordance with Example 7 of 4-bromo -51- (3-n-butoxy-4-methoxybenzylamino) -6-nitro-3 (2H) -pyridazinone (compound 29) used as a starting material, 0.29 ml of ethyl iodide, 487 mg of anhydrous carbonate potassium and 15 ml of methyl ethyl ketone, heated under reflux with stirring for 2 hours. The solvent is distilled off under reduced pressure and water is added to the residue, the mixture is extracted with chloroform, the extract is washed with a saturated aqueous solution of sodium chloride and dried over sodium sulfate, the solvent is distilled off. The residue obtained is purified by thin-layer chromatography on silica gel using a mixture of chloroform and methanol solvents (with a volume ratio of 9: 1) as eluent. The oily substance is crystallized from a mixture of diethyl ether and n-hexane to give 180 mg of the title compound with a mp. 108-110,5 ° C in the form of light yellow crystals.
NMR spectrum: 6.78 (3H, S), 5, L 3.8 (9H, t), 3.80 (3H, S), 2.0-1.4 (4H, t), 1.25, 0.95 (each 3H, t).
Mass spectrum (m / e): 424 (M), 345, 193 (100%), 137.
In addition, this compound is also obtained by the same reduction of 2-ethyl-4-bromo-5 - - (3-n-butoxy-4-methoxybenzylamino) -6-nitro-3 (2H) -pyridazinone (compound 31) which is described in Example 3.
Example 12. 2-Ethyl-4-chloro-5- - (3n-propoxy-4-methoxy-benzylamino) -6-hydroxy-3 (2H) -pyridazinone (compound 43)
% JLci O-n-Pr
Tiv NCH7-- rVOMe
ILIu /
he N
A mixture containing 523 mg of 2-ethyl-4,5-dichloro-6-hydroxy-3 (2H) -pyridainoinone obtained in Example 1, 1.71 g H-n-propocoi-4-methoxybenzylamine, 15 ml of 1,4-dioxane and 15 ml of water, heated under reflux with stirring for 24 hours, after
ten
1.71 g of Hn-propoxy-4-methoxybenzylamine is added to this mixture and i is stirred under the same conditions for 2 days. The solvent is distilled off under reduced pressure. Dilute hydrochloric acid is added to the resulting residue, the mixture is extracted with ethyl acetate. The extract is washed with water and a saturated aqueous solution of sodium chloride in this order and dried over sodium sulfate. The solvent is then distilled off to form a yellow oily substance, which is purified by silica gel column chromatography using a mixture of benzene and ethyl acetate (with a volume ratio of 1: 2) as eluent. A light yellow oily substance crystallized from ethyl acetate and diethyl ether to give 418 mg of the title compound with a m.p. 73-74 ° C (ethyl acetate - diethyl ether) in the form of colorless crystals. NMR spectrum cf: 7.79 (1H, broad S), 6.79 (3H, S), 5.4-5.0 (1H, m), 6.9- 6.4 (2H, m), 3 , 92 (2H, t), 3.81 (3H.S), 35 1.82 (2H, hexazalet), 1.17, 1.01 (each 3H, t).
Mass spectrum (m / e): 367 (M); 332, 179 (100%), 137.
Example 13. 2-Ethyl-4-chloro-5- - (3n-propoxy-4-methoxybenzylamino) -6-ethoxy-3 (2H) -pyridazinone (compound 50)
ABOUT
water is added to the residue and it is extracted with ethyl acetate. The extract is washed with water and a saturated aqueous solution of sodium chloride in this order and dried over sodium sulfate. The solvent is distilled off to form a light yellow, viscous oily substance. After crystallization from a mixture of diethyl ether and n-hexane, 158 mg of the title compound are obtained with a m.p. 77.5-78 ° C in the form of colorless crystals.
An NMR spectrum of 6.7 (3H, S), 5.0- 15 4.6 (ZN, t), 4.60, 4.40 (each 2H, g), 3.93 (2H, t), 3, 81 (3H, S), 1.84 (2H, hexazalet), 1.35, 1.29, 1.04 (each 3H, t).
cm
Infrared spectrum (-0MO (Kt
20 3280, 1625, 1605, 1530.
Mass spectrum (t / e): 395 (M4), 360, 179 (100%), 137.
B. 300 mg of 2-ethyl-4-chloro-5- (3-n-propoxy-4-methoxybenzylamino) -625-nitro-3 (2H) -pyridazinone (compound 24) obtained in Example 8 is dissolved in 6 ml of dry ethanol and to the mixture is added 160 mg of sodium ethylate. This mixture was carefully heated under reflux with stirring for 10 minutes. After cooling, ice water was poured into the reaction solution, after which most of the ethanol was distilled off under reduced pressure. The residue is extracted with ethyl acetate. The extract is washed with 1N. a solution of hydrochloric acid, water and a saturated aqueous solution of sodium chloride in the indicated order and dried with sodium sulfate. The solvent is distilled off and the resulting oily substance is purified by thin layer chromatography on silica gel using as eluent
45 mixtures of benzene and ethyl acetate (in a 7: 3 weight ratio), resulting in 300 mg of the indicated compound. The physical properties and the data of the NMR spectrum, the infrared spectrum and A. A mixture containing 184 mg of 2-ethyl 5 about the mass spectrum of this compound fully-4-chloro-5- (3-n-propoxy-4-methoxybency) is consistent with similar byEW
0-n-Pt
N NCHa-CS-Otte OEt H
Zylamino) -6-hydroxy-3 (2H) -pyridazinone (compound 43) obtained in Example 12, 156 mg of ethyl iodide, 207 mg of anhydrous potassium carbonate and 15 ml of methyl ethyl ketone are heated under reflux with stirring for 2 hours. The solvent is distilled off under reduced pressure. To received
55
Kazatami compounds obtained in accordance with the presented method A.
Example 14. 4,6-Dichloro-5- (3-n-propoxy-4-methoxybenzylamino) -3 (2H) -pyridazinone (compound 71)
water is added to the residue and it is extracted with ethyl acetate. The extract is washed with water and a saturated aqueous solution of sodium chloride in this order and dried over sodium sulfate. The solvent is distilled off to form a light yellow, viscous oily substance. After crystallization from a mixture of diethyl ether and n-hexane, 158 mg of the title compound are obtained with a m.p. 77.5-78 ° C in the form of colorless crystals.
NMR spectrum 6.7 (3H, S), 5.0-4.6 (ZN, t), 4.60, 4.40 (each 2H, g), 3.93 (2H, t), 3.81 (3H, S), 1.84 (2H, hexazalet), 1.35, 1.29, 1.04 (each 3H, t).
cm
Kazatami compounds obtained in accordance with the presented method A.
Example 14. 4,6-Dichloro-5- (3-n-propoxy-4-methoxybenzylamino) -3 (2H) -pyridazinone (compound 71)
A mixture containing 997 mg of 4,5,6-trichloro-3 (2H) -pyridazinone, 3.20 g of H-n-propoxy-4-methoxybenzylamine and 30 ml of ethanol is heated under reflux with stirring for 2 hours. Ethanol was distilled off under reduced pressure, and diluted hydrochloric acid was poured into the resulting residue, and the mixture was extracted with ethyl acetate. The extract is washed with water and dried over sodium sulfate. The solvent is then distilled off to form a light brown, viscous, oily substance. The residue is purified by chromatography on a column of silica. and separating the second fraction obtained by elution with a solvent mixture containing benzene and ethyl acetate (with a volume ratio of 2.5: 1), which allows to obtain a colorless solid. After crystallization, 513 mg of the title compound are obtained with a mp. 181-183 ° C (methanol - diethyl ether) in the form of colorless crystals.
Nuclear Magnetic Resonance Spectrum (CDC13 + DMSO-d 4) cC: 12.72 (1H, broad-S), 6t79 (3H, S), 6.0-5.6 (1H, m), 4.78 (2H, d), 3, -91 (2H, t), 3.79 (3H, S), 1.80 (2H, hexane), 1.02 (3H, t).
Mass Spectrum- (m / e): 357 (M +), 322, 179 (100%), 137.
Example 15. 2-Ethyl-4,6-dichloro-5- (3-n-propoxy-4-methoxybenzylamino) -3 (2H) -pyridazinone (compound 62)
El o
Aus10-p-Pr
NV NCHrO 0Me C1 N
A. A mixture containing 150 mg of 4,6- -dichloro-5- (3-n-propoxy-4-methoxy-benzylamino) -3 (2H) -pyridazinone (compound 71) obtained in Example 14, 0.2 ml of ethyl iodide , 116 mg of anhydrous potassium carbonate and 10 ml of methyl ethyl ketone, heated under reflux with stirring for t hours. The reaction mixture is distilled under reduced pressure, and water is poured into the residue. The mixture is extracted
ethyl acetate. The extract is washed with water and dried over sodium sulfate. The solvent is then distilled off to form a light yellow, viscous, oily substance. The product is crystallized from a mixture of diethyl ether and n-hexane, yielding 139 mg of the title compound.
0 s. 101-103PC in the form of colorless crystals.
NMR spectrum: 6.83 (3H.S), 4.80 (3N, wide S), 4.12 (2H, g), 3.96 (2H, t), 3.84 (3H, S), 1.86 (2H, hexa5 years), 1.34, 1.05 (each 3N, t).
Mass spectrum (m / e): 385 (M), 350, 179 (100%), 137.
B, a mixture containing 455 kg of 2-ethyl- -4,5,6-trichloro-3 (2H) -pyridazinone,
0 1.20 g H-n-propoxy-4-methoxybenzylamine and 20 ml of ethanol, heated under reflux with stirring for 3.5 hours. Ethanol is distilled off under reduced pressure and water is then poured into the residue thus obtained. The mixture is extracted with ethyl acetate. The extract is washed with dilute hydrochloric acid and water in this order and dried over sodium sulfate. The solvent is then distilled off to form a light brown, viscous, oily substance. This product is purified by chromatography on silica gel columns using
. by setting the mixture of benzene and ethyl acetate (with a volume ratio of 15: 1) as eluent, resulting in 277 mg of the indicated compound. The physical properties and spectral data of NMR spectroscopy and mass spectroscopy of this compound are in full agreement with similar indicators of the compound obtained using method A.
5 Example16. 4-Chloro-5- (3-n-butoxy-4-methoxybenzylamino) -6-ethoxy-3 (2H) -pyridazinone (compound 68)
50
NAyClO-AND-BU
lsl NCH2- -OMe OEl H
A mixture containing 7.32 g of 4,5-dichloro-6-ethoxy-3 (2H) -pyridazinone obtained in Example 2, 21.95 g of 3-n-butoxy-4-methoxybenzylamine, 60 ml 1, 4-dioxane and 60 ml of water are heated under reflux with stirring for 15 hours. Then, the pain 1} of the 1,4-dioxane is distilled off under reduced pressure and acidified and diluted hydrochloric acid is added. After that, chloroform is added and the mixture is shaken vigorously. The precipitated crystals are separated by filtration, the chlorooam in the filtrate is separated from the liquid and washed with water and dried over sodium sulfate. The solvent is distilled off to form a light yellow oily substance. The product is cris- ~ gallized from n-propanol and diisopropyl ether (with an OBI ratio of 1: 9) to give 10.48 g. Indicated a jroro compound with m.p. 117 - 118 С r in the form of colorless crystals.
NMR Spectrum G: 11.79 (1H, broad b), 6.76 (3H.S), 5.2-4.8 (W, t), 4.80, 71 (2H, d), 4.19 (2H, g), 3.96 (2H, t) Ј, 81 (3H, S), 2.1-1.3 (4H, ra), 1.32,
, 97 (each 3H, t).
, Mass Spectrum (m / e): 381 (Mf), 346, 193 (100%), 137.
P p and m e p 17. 4-Chloro-5- (3-etho-: i-4-methoxybe "zylamino) -6-sec, -butoxy-3 (2H) -pyridazinone (compound 88)

n o
vyci
Oet
Nyi-NHCH1- -OMe 0-SeOBu
A mixture containing 150 mg of 2- (2-trimethylsilyl ethoxymethyl) -4-chloro-5 (3--ethoxy-4-methoxybenzylamino) -6-sec, - -butoxy-3 (2H) -pyridazinone obtained in Example 4 , 1.46 ml of tetra-n-butylammonium fluoride (1 M solution of tetrahydrofuran) and 5 ml of 1,2-dimethoxyethane are heated under reflux with stirring for 3 hours. The solvent is distilled off under reduced pressure, and the resulting residue is extracted chloroform. The extract is washed twice with 1N. a solution of hydrochloric acid and once with water in this order, after which it is dried over sodium sulfate, the solvent is distilled off to form a dark brown oily substance. The oily substance is purified by preparative thin-layer chromatography on silica gel using
five
ethyl acetate as eluent, resulting in a light yellow solid. After crystallization from a mixture of chloroform and diethyl ether, 50 mg of the title compound is obtained, m.p. 130.5-132 ° C in the form of yellowish crystals.
NMR spectrum (CDC13 + DMSO-d6) f: 11.70 (1H, S), 6.70 (3H, S), 5.02 (2H, m), 4.81, 4.74 (2H, d) , 4.05 (2H, g), 3.82 (3H, S), 1.50 (9H, m), 1.00 (2H, m).
Mass spectrum (m / e): 381 (M), 346, 165 (100%).
The compounds obtained in the same manner as in the examples considered are listed in Table 1. The number of the example in the right column indicates the example, according to but the connection.
which get5
0
five
0
five
0
five
A. Test for antagonistic action against SRS-A.
SRS-A is a mixture of leukotrin C, p (hereinafter defined as LTC4), leucogrin L) 4 (LTD 4), leukotrika E4 (TETS) for similar substances. The antagonistic effect on SRS-A can be assessed by one of the following two test methods: an antagonistic study method for SRS-A obtained from a sensitized guinea pig antagonistic action method for LTC4, LTD4 or LTE4o
In studying the antagonistic effect of the compounds of formula (I) with respect to SRS-A, the following test methods are used.
Laboratory test. Antagonism against LTD, in the guinea pig trachea.
Antagonism against LTD4 is determined in the separated trachea of a male guinea pig (300-400 g), prepared in the form of a spiral strip. The tracheal preparations are suspended with a tension of 1 g in 10 ml trays for organs containing 5 µmol indidetacin, after which they are incubated for 1 hour prior to use. The contraction reactions of LTD (2x10 8 g / ml) are determined after establishing the maximum response to histamine (10 mol). Test compounds dissolved in 100%
cymepsulphoxide, added to organ baths (final concentrate
10 g / ml or 10 7 g / ml) 30 minutes before adding LTD, after which the reduction reactions under the influence of LTD.J are compared with the reactions of control samples, which are obtained from
pair trachea in the absence of the tested compounds. The abbreviations caused by LTD are expressed as a percentage of the maximal response to histamine. Antagonism is defined as follows:
Antagonism% - ------ ° -ЈйЕЈ ™ -У-We experience #and 5 samples
% reduction in control samples
Test in vivo. The effect on the anaphylactic contraction of the bronchial muscle under the effect of the endogenously isolated SRS-A in a free state in passively sensitized guinea pigs.
Male guinea pigs (350–450 g) are passively sensitized by intravenous injection of 0.125 ml of anti-ovalbumin rabbit serum for 1–2 days. before the experiment. Anaphylactic contractions of the bronchial muscle caused by the antigen under the influence of the isolated and free state endogenously by SRS-A are measured using the modified method of Konzett and Rossler. Sensitized guinea pigs are anesthetized by intraperitoneal injection of urethane (1.5 g / kg). A cannula is inserted into the right strap vein to inject all agents, after which a cannula is also inserted into the trachea to record the total pulmonary resistance. Guinea pigs are given artificial respiration with a small animal respirator (Shinano, model SN-480-7), for which a systolic volume of 4.5 ml has been established, and the respiratory rate is 50 breaths per minute. The change in pulmonary resistance is measured using a pressure transducer (Nihon Coden, model TR-602T) connected to a T-shaped tube in a cannula located in the trachea. The increase in the volume of excreted air is expressed as a percentage of the maximum reduction in bronchial muscle achieved as a result of tracheal clamping. Following the surgical preparation, indomethacin (2 mg / kg, 10 min), pyrilamine (2 mg / kg, 6 min) and propranolol (0.1 mg / kg, 5 min) were administered to the animals before infection with ovalbumin (0.2 mg / kg). All test100.
five
0
five
0
five
0
five
0
five
These compounds are administered orally 2 hours before infection with ovalbumin. The inhibition (%) of bronchial muscle contraction was determined as follows: braking,% (1.0 -% of the maximum reduction of bronchial muscle in the test group) x (% of the maximum reduction of bronchial muscle in the control group) x100. The maximum reduction in bronchial muscle was 62 + 6% (mean i, standard deviation-ej) and the number of test animals was 5-6.
Test results
Laboratory test. The antagonism values for LTD4 achieved by the test compounds at a concentration of g / ml are shown in Table 2. In parentheses are the values of antagonism against LTD,}, achieved using test compounds at a concentration of g / ml.
Data are presented in comparison with known compounds (a compound of formula (I) in which the sixth position of the pyridazine ring is unsubstituted). Those. The known proposed compounds are similar in structure with the exception of the substituent in the sixth position of the pyridazine cycle. The results are shown in the table.
Test in vivo. Each of the tested compounds 68 and 69, which are typical of the proposed compounds, showed a significant inhibitory effect compared with the control compound at the dose administered through the mouth, which is listed in Table 2 (P 0.05). The results are shown in table 4.
Acute toxicity test. The mortality ratio was determined in male CD-1 (1CR) mice (5 weeks old) after 7 days. after ive191
Denis cher the mouth of the tested compounds. The results are shown in table 5.
Based on these results, it can be concluded that the proposed compounds exhibit a pronounced antagonistic effect on SRS-A and its main components, peptide leukotrins, both when tested in laboratory conditions and when tested in vitro. living organisms. In addition, the compounds are characterized by a strong pharmacological action and have low {toxicity even when administered by mouth. Therefore, the proposed compounds will be useful as prophylactic and therapeutic drugs for various immediate-type allergic diseases such as bronchial sialvitis, allergic rhinitis, Urticaria and senna fever, various inflammatory diseases such as rheumatoid arthritis, spondiosis. th arthritis or ihaemia diseases of the heart b. a such as angina pectoris and myocardial infarction caused by srs-a or one of them (peykotrins c4, d4 and e4, as its components or their mixtures.

权利要求:
Claims (1)
[1]
Invention Formula
The method of obtaining derivatives of 3 (2H) - -pyridazinone General formula
R
Nv
tV-NCVh- J-z, Y
R is hydrogen, Cj-C is alkyl of normal or iso-structure, Rj is hydrogen, С Сэ-alkyl; X is chlorine or bromine; Y is hydrogen, the nitro group / -NH
AR
four
where A is oxygen,
g
hydrogen, Ci-Cj-alkyl of normal or branched structure, Ce-Cfc-alkenyl, 50
C-alkynyl, or
, -CHR5 city, With
loid;
OR4 where
C, C
branched out
where Ri is bo- - C, -alkyl or haR hydrogen, of normal structure
or or
- (CH) n
where n 1-4;
Zz is a C1-4 alkoxy group provided that if R is alkyl, then Y is not hydrogen, and if R is hydrogen, then Y and R2 are not hydrogen at the same time, characterized in that the compound of the general formula
I
Xx
Ya
(and)
x
Yn
where R is hydrogen, C, -C-alkyl; chlorine or bromine hydrogen, nitro, amino, AR4, where A is oxygen, R4 is hydrogen, C, -C6-alkyl of normal or branched structure or halo,
is reacted with an amine of the formula
us-sn
Ro
(Iii)
where Ri, Z 1 and Z have the indicated meanings, optionally in the presence of an acid binding substance to produce 3 (2H) tpiridazinone of the formula
oh
i "v ... p y
Lu
(1a)
Ya R
five
0
five
Where
R1
R
g
or,
hydrogen, -alkyl normal or isostrate, X, Z and Z have the indicated
meanings
if Y is a nitro group, compound 1a is reduced to obtain a compound of formula I, where Y is NH 2, or is reacted with a compound of formula MfOR4, where Mt is an alkali metal and R4 has the indicated values, to form the corresponding compound of formula I, where Y is OR4 and R4 is as defined, or alkylated to give the corresponding compound of formula I, where R is —C — C — alkyl.
27
158475028
Table 2

类似技术:

公开号 | 公开日 | 专利标题

SU1584750A3|1990-08-07|Method of producing derivatives of 3|-pyridazinone

US4654342A|1987-03-31|6-|pyridazinones as cardiac stimulants

RU2124016C1|1998-12-27|Pyrazolopyrimidines and their pharmaceutically acceptable salts

SU1287748A3|1987-01-30|Method of producing arylopropanolamines or pharmaceutically acceptable salts |

KR100812586B1|2008-03-13|Quinazoline compounds useful as p38 kinase inhibitors

US3995039A|1976-11-30|Pyrazolo [1,5-a] [1,3,5] triazines

EP0877734A1|1998-11-18|Quinoline and quinazoline compounds useful in therapy

KR910005233B1|1991-07-24|Pyridazinone derivatives

PL136217B1|1986-02-28|Method of obtaining novel derivatives of 4-amino-6,7-dimetoxy-2-piprazinoquinazoline

US4513135A|1985-04-23|Diaryl-pyrazine derivatives affecting GABA binding

EP0376079A1|1990-07-04|3|pyridazinones, processes for their preparation and antagonistic agent against SRS-A

EP0186817A1|1986-07-09|3|pyridazinone, process for its preparation and anti-allergic agent containing it

SU1503681A3|1989-08-23|Method of producing derivatives of 1-|-5n-2,3-benzodiazepine

KR20000064716A|2000-11-06|Pharmaceutically useful compounds

US4767780A|1988-08-30|Benzene-fused heterocyclic compound and their use as diuretics

US5340814A|1994-08-23|3-substituted methyl-2,3-dihydroimidazo[1,2-C] quinazoline derivatives, the preparation and use thereof

NZ223683A|1990-04-26|Dihydropyridazinone derivatives and pharmaceutical compositions

US4766123A|1988-08-23|Methylamidine compounds

RU2279433C2|2006-07-10|New compound for impotence treatment

EP0538477B1|2002-10-16|Novel cyclic aminophenylacetic acid derivative, production thereof, and immune response modulator containing the same as active ingredient

US4657922A|1987-04-14|Anxiolytic 4,5-dihydro-4-oxo-1H-imidazol-2-yl urea derivatives

EP0252422B1|1991-07-24|Pyridazinone derivatives and salts thereof

Bosin et al.1973|Routes of functionalized guanidines. Synthesis of guanidino diesters

EP0089528A1|1983-09-28|6-Aryl-4,5-dihydro-3|-pyridazinones, their preparation and use

JP7025555B2|2022-02-24|Inhibition of transient receptor potential A1 ion channels

同族专利:

公开号 | 公开日

AU597141B2|1990-05-24|

AU1039688A|1988-07-21|

EP0275997B1|1992-12-23|

EP0275997A1|1988-07-27|

HUT46313A|1988-10-28|

ZA88309B|1988-07-01|

DE3876813D1|1993-02-04|

DE3876813T4|1995-05-11|

US4978665A|1990-12-18|

HU198696B|1989-11-28|

DD287497A5|1991-02-28|

DE3876813T2|1993-04-29|

AT83773T|1993-01-15|

CA1324792C|1993-11-30|

引用文献:

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

CA784639A|1968-05-07|C. Olson Harold|Herbicidal compositions|

FR1441438A|1963-11-13|1966-06-10|Basf Ag|Process for the preparation of 4-nitro-5-amino pyridazones-6|

FR1413955A|1964-06-03|1965-10-15|Basf Ag|Process for the preparation of 4-amino-5-halogeno-6-pyridazones|

US4296120A|1980-08-28|1981-10-20|Pfizer Inc.|phenylalkenamides and esters thereof as SRS-A antagonists|

CA1265798A|1984-12-10|1990-02-13|Motoo Mutsukado|3pyridazinone, process for its preparation andanti-allergic agent containing it|

US4892947A|1985-04-27|1990-01-09|Nissan Chemical Industries Ltd.|3Pyridazinone, process for its preparation and anti-allergic agent containing it|CA1265798A|1984-12-10|1990-02-13|Motoo Mutsukado|3pyridazinone, process for its preparation andanti-allergic agent containing it|

IE62890B1|1988-12-06|1995-03-08|Hafslund Nycomed Pharma|New piperazinylalkyl-3-pyridazinones process for the preparation thereof and the use thereof as agents lowering blood pressure|

DE4009761A1|1989-07-28|1991-01-31|Bayer Ag|2H-pyridazinone derivatives|

JPH07107055B1|1990-04-25|1995-11-15|

IL110040A|1993-06-29|2000-07-16|Nissan Chemical Ind Ltd|Pyridazinone derivatives their preparation and pharmaceutical compositions comprising them|

EP0717734B1|1993-09-06|1998-11-18|Ishihara Sangyo Kaisha, Ltd.|Pyridazinone derivatives or their salts, processes for their production, and anti-shock agents containing them|

NZ270130A|1993-12-16|1995-12-21|Nihon Nohyaku Co Ltd|Pyridazinone derivatives, preparation and pharmaceutical compositions thereof|

AT192741T|1994-01-25|2000-05-15|Nissan Chemical Ind Ltd|PYRIDAZINONE DERIVATIVES|

IL112695A|1994-02-22|1999-04-11|Green Cross Corp|Pharmaceutical compositions containing pyridazinone derivatives|

DE19516350A1|1995-05-04|1996-11-07|Du Pont Deutschland|Reduced fog photothermographic photosensitive material|

US20040106794A1|2001-04-16|2004-06-03|Schering Corporation|3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands|

US7132445B2|2001-04-16|2006-11-07|Schering Corporation|3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands|

JP2005505595A|2001-10-12|2005-02-24|シェーリング　コーポレイション|3,4-Disubstituted maleimide compounds as CXC-chemokine receptor antagonists|

US6878709B2|2002-01-04|2005-04-12|Schering Corporation|3,4-di-substituted pyridazinediones as CXC chemokine receptor antagonists|

PE20040570A1|2002-10-09|2004-08-30|Pharmacopeia Drug Discovery|THIADIAZOLDIOXIDES AND THIADIAZOLOXIDES AS LIGANDS OF THE CXC- AND CC-CHEMOKIN RECEPTOR|

AT406356T|2003-12-19|2008-09-15|Schering Corp|THIADIAZOLE AS CXC AND CC CHEMOKIN RECEPTOR LIGANDS|

WO2005068460A1|2003-12-22|2005-07-28|Schering Corporation|Isothiazole dioxides as cxc- and cc- chemokine receptor ligands|

CA2613428A1|2005-06-29|2007-01-11|Schering Corporation|5,6-di-substituted oxadiazolopyrazines and thiadiazolopyrazines as cxc-chemokine receptor ligands|

CA2613607A1|2005-06-29|2007-01-04|Schering Corporation|Di-substituted oxadiazoles as cxc-chemokine receptor ligands|

EP3856722A1|2018-09-27|2021-08-04|Fmc Corporation|Intermediates for preparing herbicidal pyridazinones|

法律状态:

优先权:

申请号 | 申请日 | 专利标题

JP1023187|1987-01-20|

[返回顶部]